Scarica l'app Stockscreener
2.37
0.81%
0.02
Precedente Chiudi:
$2.35
Aprire:
$2.32
Volume 24 ore:
76,229
Relative Volume:
0.22
Capitalizzazione di mercato:
$101.45M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-3.31%
1M Prestazione:
-18.31%
6M Prestazione:
-54.79%
1 anno Prestazione:
-89.81%
Intervallo 1D:
$2.29
$2.385
Intervallo di 1 settimana:
$2.20
$2.47
Portata 52W:
$2.20
$25.84
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Nome
Kyverna Therapeutics Inc
Settore
Industria
Telefono
(510) 626-8331
Indirizzo
5980 HORTON STREET, EMERYVILLE
Confronta KYTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
2.37 | 101.45M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
510.76 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
653.42 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
287.76 | 37.54B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ARGX
Argen X Se Adr
|
606.29 | 37.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
251.75 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-10 | Iniziato | UBS | Buy |
| 2024-10-09 | Iniziato | Rodman & Renshaw | Buy |
| 2024-07-03 | Iniziato | H.C. Wainwright | Neutral |
| 2024-03-04 | Iniziato | JP Morgan | Overweight |
| 2024-03-04 | Iniziato | Leerink Partners | Outperform |
| 2024-03-04 | Iniziato | Morgan Stanley | Overweight |
| 2024-03-04 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie
Notice to Long-Term Shareholders of Akero Therapeutics, - GlobeNewswire
Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is I - TradingView
Why Kyverna Therapeutics Stock Is Sinking - MSN
Investors Who Lost Money on Kyverna Therapeutics, Inc. (KYTX) Should Contact Levi & Korsinsky About Pending Class ActionKYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More Information – KYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - ACCESS Newswire
Kyverna Therapeutics Inc expected to post a loss of 84 cents a shareEarnings Preview - TradingView
Kyverna Therapeutics stock hits 52-week low at $2.24 - Investing.com
Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 - Seeking Alpha
Kyverna Therapeutics stock hits 52-week low at $2.24 By Investing.com - Investing.com South Africa
Notice to Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire
Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Clai - Morningstar
Kyverna Therapeutics (KYTX) to Release Quarterly Earnings on Tuesday - MarketBeat
Lupus Nephritis Clinical and Non-Clinical Studies, Key - openPR
GordonMD® Invests in Clinical Stage Cell Therapy Company Kyverna - Business Wire
Notice to Long-Term Shareholders of Archer-Daniels-Midland - GlobeNewswire
Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Notice to Long-Term Shareholders of Fluence Energy, Inc. - GlobeNewswire
Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: - GlobeNewswire
KYTX stock touches 52-week low at $2.49 amid market challenges - Investing.com Australia
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Rhumbline Advisers Purchases 6,153 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics stock hits 52-week low at $2.64 By Investing.com - Investing.com Australia
Kyverna Therapeutics to Present at the Leerink Partners Global B - GuruFocus.com
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference - PR Newswire
Kyverna Therapeutics stock hits 52-week low at $2.64 - Investing.com
Levi & Korsinsky Notifies Shareholders of Kyverna Therapeutics, Inc. (KYTX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Kyverna Therapeutics To Present At The Leerink Partners Global Biopharma Conference - MENAFN.COM
KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Head-To-Head Survey: Pluri (NASDAQ:PLUR) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. LawsuitKYTX - ACCESS Newswire
3 US Penny Stocks With Market Caps Under $200M - Yahoo Finance
KYTX stock touches 52-week low at $2.78 amid sharp annual decline - MSN
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $25.71 Consensus Price Target from Analysts - Defense World
KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Leerink Partnrs Issues Optimistic Estimate for KYTX Earnings - MarketBeat
KYTX stock touches 52-week low at $2.78 amid sharp annual decline By Investing.com - Investing.com South Africa
Equities Analysts Set Expectations for KYTX FY2025 Earnings - Defense World
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock - MSN
KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - Morningstar
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - Kilgore News Herald
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadli - GuruFocus.com
2025-02-07 | FINAL REMINDER KYTX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Kyverna Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit | NDAQ:KYTX | Press Release - Stockhouse Publishing
The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - TradingView
Kyverna Therapeutics Inc Azioni (KYTX) Dati Finanziari
Non sono disponibili dati finanziari per Kyverna Therapeutics Inc (KYTX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Kyverna Therapeutics Inc Azioni (KYTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Jones Ryan Alexander | Chief Financial Officer |
May 28 '24 |
Option Exercise |
0.73 |
18,016 |
13,152 |
43,950 |
1.39%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):